Literature DB >> 25964305

Reflex Human Papillomavirus Test Results as an Option for the Management of Korean Women With Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion.

Ki-Jin Ryu1, Sanghoon Lee1, Kyung-Jin Min1, Jae Won Kim1, Jin Hwa Hong1, Jae Yun Song1, Jae Kwan Lee1, Nak Woo Lee2.   

Abstract

BACKGROUND: Current guidelines recommend initial colposcopy with biopsy regardless of human papillomavirus (HPV) test results in women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H). The purpose of this study was to evaluate the value of HPV testing in women with ASC-H based on colposcopic pathology results.
MATERIALS AND METHODS: A multicenter cross-sectional study was carried out at three academic hospitals and involved 40,847 Korean women who underwent cervical cancer screening with cytology and HPV tests with or without subsequent colposcopic biopsies between January 2007 and December 2013.
RESULTS: ASC-H was diagnosed in 276 women (0.7%). Only 6 of 68 (8.8%) women with ASC-H who were HPV negative had cervical intraepithelial neoplasia grade ≥2 (CIN ≥2) lesions, whereas 47.4% of the women with ASC-H who were HPV positive had CIN ≥2 lesions. No cases of invasive cervical cancer were diagnosed among women with ASC-H who were HPV negative. Logistic regression analysis was performed using the group with normal Papanicolaou test results and HPV-negative status as the reference group. Women with ASC-H who were HPV positive had a significantly increased risk of CIN ≥2 lesions, whereas no significant increase was observed in patients with ASC-H and HPV-negative status.
CONCLUSION: If the result of the HPV test was negative, the risk of CIN ≥2 lesions in Korean women with ASC-H cytology was low. Reflex HPV testing should be an option for the management of women with cytology showing ASC-H to decrease unnecessary colposcopic biopsies, which are expensive and invasive. IMPLICATIONS FOR PRACTICE: Current American Society for Colposcopy and Cervical Pathology guidelines recommend universal colposcopy for the management of women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H) on cytology, regardless of human papillomavirus (HPV) test results. The present study suggested that HPV cotesting in patients with ASC-H cytology can provide more detailed and useful information regarding the risk of high-grade cervical intraepithelial neoplasia (CIN) lesions and the need for further treatment. When the result of the HPV test was negative, the risk of CIN lesions of grade ≥2 in women with ASC-H cytology was low. Consequently, reflex HPV testing, rather than immediately performance of invasive and expensive colposcopy with biopsy, should be an option for the management of women with ASC-H. ©AlphaMed Press.

Entities:  

Keywords:  Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion; Cervical cancer; Cervical intraepithelial neoplasia; Colposcopy; Human papillomavirus; Papanicolaou test

Mesh:

Year:  2015        PMID: 25964305      PMCID: PMC4571782          DOI: 10.1634/theoncologist.2014-0459

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  25 in total

1.  Adjunctive human papillomavirus DNA testing is a useful option in some clinical settings for disease risk assessment and triage of females with ASC-H Papanicolaou test results.

Authors:  Sudeshna Bandyopadhyay; R Marshall Austin; David Dabbs; Chengquan Zhao
Journal:  Arch Pathol Lab Med       Date:  2008-12       Impact factor: 5.534

2.  Clinical significance of atypical squamous cells cannot exclude high grade squamous intraepithelial lesion with histologic correlation-: a 9-year experience.

Authors:  Suzanne M Selvaggi
Journal:  Diagn Cytopathol       Date:  2013-06-08       Impact factor: 1.582

Review 3.  Atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion: review of ancillary testing modalities and implications for follow-up.

Authors:  Diane Davis Davey; David L Greenspan; Daniel F I Kurtycz; Mujtaba Husain; R Marshall Austin
Journal:  J Low Genit Tract Dis       Date:  2010-07       Impact factor: 1.925

4.  Follow-up of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesions (ASC-H).

Authors:  Fanny López-Alegría; Dino Soares De Lorenzi; Orlando Poblete Quezada
Journal:  Sao Paulo Med J       Date:  2014       Impact factor: 1.044

5.  Cervical cancer screening: the complex interplay of medical infrastructure, society, and culture.

Authors:  Annekathryn Goodman; Nawal Nour
Journal:  Oncologist       Date:  2014-03-28

6.  Cervical cytology with a diagnosis of atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion (ASC-H): a follow-up study with corresponding histology and significance of predicting dysplasia by human papillomavirus (HPV) DNA testing.

Authors:  Syed M Gilani; Randy Tashjian; Lamia Fathallah
Journal:  Arch Gynecol Obstet       Date:  2013-09-04       Impact factor: 2.344

7.  Reflex high-risk human papilloma virus DNA test is useful in the triage of women with atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion.

Authors:  Howard Her-Juing Wu; Susan L Allen; Joseph L Kirkpatrick; Tarik M Elsheikh
Journal:  Diagn Cytopathol       Date:  2006-10       Impact factor: 1.582

Review 8.  Vaccines against human papillomavirus and cervical cancer: promises and challenges.

Authors:  Ali Mahdavi; Bradley J Monk
Journal:  Oncologist       Date:  2005-08

9.  Current cervical cancer screening knowledge, awareness, and practices among U.S. affiliated pacific island providers: opportunities and challenges.

Authors:  Julie S Townsend; Analía Romina Stormo; Katherine B Roland; Lee Buenconsejo-Lum; Susan White; Mona Saraiya
Journal:  Oncologist       Date:  2014-03-25

10.  Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials.

Authors:  Guglielmo Ronco; Joakim Dillner; K Miriam Elfström; Sara Tunesi; Peter J F Snijders; Marc Arbyn; Henry Kitchener; Nereo Segnan; Clare Gilham; Paolo Giorgi-Rossi; Johannes Berkhof; Julian Peto; Chris J L M Meijer
Journal:  Lancet       Date:  2013-11-03       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.